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1. Introduction 
Currently, i.v. thrombolysis with recombinant tissue plasminogen activator (r-TPA) in acute 
ischemic stroke is approved in Europe only for patients 80 y.o. or younger, but data from the 
literature do suggest that patients older than 80 might also benefit from it (Sanossian and 
Ovbiagele, 2009). These older patients do have a worse outcome than younger ones, a 
finding that seems to be due to worse baseline prognostic factors, but they are not more 
prone to r-TPA -induced haemorrhage than younger ones (Engelter et al., 2006; Toni et al., 
2008). Based on these considerations, a randomized clinical trial of i.v. r-TPA vs. usual care 
in acute stroke in patients older than 80 years is currently under way in Italy.  
Even lesser data are available for stroke patients older than 90 years. Recently, it has been 
suggested that these patients may not benefit significantly from i.v. r-TPA, despite the fact 
that this treatment appeared reasonably safe in this age range, too (Mateen et al., 2009; 
Mishra et al., 2010).  
We are reporting our experience with i.v. r-TPA in patients 90 year old or older in acute 
ischemic stroke.  
2. Patients and results 
We treated with i.v. r-TPA for acute stroke 6 patients (1male, 5 females). Median age was 
92.5 y.o. (range 90-95). In all cases a CT scan had ruled out haemorrhagic stroke, and there 
were none of the exclusion criteria of the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST (Wahlgren et al., 2007)), apart from age and (in some cases, 
see below) elapsed time from onset of stroke. Specifically, all patient were in good 
neurological conditions before stroke. Modified Rankin Scale (mRS) before stroke was 0 or 1 
in all cases, except in one 91 y.o. female where it was 3 due to severe hip arthrosis (no pre-
existing neurological deficit). Risk factors were none (in 2 patients), hypertension  
(3 patients), previous minor stroke more than 3 months before the index one (2 patients), 
atrial fibrillation (2 patients), diabetes (1 patient). No patient had cognitive impairment. 
In all cases a written informed consent was obtained either from the patient through a 
witness (n = 3) or from a first degree relative (n = 3). 
www.intechopen.com
 
Advances in the Treatment of Ischemic Stroke 
 
164 
The median National Institute of Health Stroke Scale (NIHSS) on presentation was 17.5 
(range 3-21). It should be noted that that in the single case where NIHSS was less than 6, the 
symptoms included aphasia, a condition that is considered to be very disabling, thus worth 
the risk of thrombolysis (Kohrmann et al., 2009). All strokes were in the carotid arteries 
territory. Stroke was due to cardiac emboli in 3 cases and to large vessel disease in 2 cases; 
the remaining case was a lacunar stroke in the basal ganglia area. Median stroke-to-hospital 
time was 84.50’ (range 32’-102’). Upon their arrival into the Emergency Room the advanced 
age of these patients caused them to be initially excluded from thrombolytic treatment, 
therefore they were not handled in the rapid way that prospective r-TPA patients are 
usually treated. Only later the consulting stroke neurologist considered thrombolysis as an 
option. Thus, in-hospital times were rather slow. Median door-to-CT time was 82’ (range 
39’-147’), median CT-to-treatment time was 49.5’ (range 15’-110’). Median door-to-treatment 
time was 150.5’ (range 80’-215’). Median time from stroke onset to thrombolysis (“stroke-to-
needle” time) was 210’ (range 177’-273’). 
Four patients received the standard r-TPA dose of 0.9 mg/Kg i.v., 10% of which was 
administered as an initial bolus, followed by the remaining 90% over 1h. One 94 y.o. patient 
received the lower dose of 0.67 mg/Kg i.v. (10% as a bolus, 90% in 1h) because in the 
Emergency Room she had already been given 500 mg acetyl-salicylic acid i.v. in the belief 
that she was not a candidate to thrombolysis. This same patient suffered shortly after 
thrombolysis a traumatic clavicle fracture, after which a major bleeding, requiring 
transfusion, occurred around the site of fracture. In another 91 y.o. patient r-TPA infusion 
was stopped after 25’ (when about 50% of the full dose had been administered) because of 
headache and a minor gingival bleeding. It should be noted that minor gingival bleeding 
occurred during drug infusion in another 91 y.o. patient who nevertheless went on to 
receive the full standard dose of r-TPA with no other harmful consequences. No bleeding 
was observed in the other patients.  
No symptomatic intracranial haemorrhage occurred in any patient. In 1 patient a 
haemorrhagic transformation of the stroke (categorized HI2 according to ECASS III 
classification (Hacke et al., 2008)) was seen at the 24 hours follow-up CT scan, in all other 
cases no bleeding was observed at routine 24 hours follow-up CT scan.  
In 3 patients transcranial ultrasound examination was carried out both before and 
immediately after thrombolysis. In all these cases occlusion of the middle cerebral artery 
was found, graded 0 (1 case) or 2 (2 cases) according to the TIBI classification (Demchuk et 
al., 2001). In all these cases improvement of flow to a TIBI 3 score was noted after 
thrombolysis. It should be noted that these are the 3 patients that showed good outcome 
at the 3-months follow up (mRS=0-1). In one of the 3 cases where ultrasound examination 
could not be carried out, a dense middle cerebral artery sign (Launes and Ketonen, 1987) 
was found upon non-contrast CT scan before thrombolysis. This patient showed an 
almost full recovery of motor function at the end of tPA infusion, that was followed by 
worsening 1 hour after. A CT scan right after the second worsening ruled out any 
intracranial bleeding. We interpret these findings as r-TPA -induced recanalization 
followed by early restenosis. 
Figure 1 shows the NIHSS score before thrombolysis and at various times after it. As it 
can be seen, both patients with milder symptoms (NIHSS=3 and 6, respectively) had very 
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good outcome (NIHSS=1 and 0, respectively, after 7 days). Of the 4 patients with more 
severe symptoms, 1 had very good improvement (NIHSS=1 after 7 days – this is the lady 
who received 0.67 mg/Kg because she had already received 500 mg ASA), the other 3 had 
minimal or no improvement. Of the latter 3 ones, 1 is the lady whose treatment was 
aborted because of gingival bleeding, and the other 2 are the patients who later died (see 
below).  
 
Fig. 1. NIHSS score before thrombolysis and 2 hours, 24 hours and 7 days after it in each 
patient. One asterisk indicates the patient in whom treatment was aborted before of gingival 
bleeding after 25’, when approximately 50% of the full rTPA dose had been received. Two 
asterisks indicate the patient to whom the reduced rTPA dose of 0.67 mg/Kg was 
administered because she had already received 500 mg ASA i.v. 
Figure 2 shows the score on the modified Rankin Scale (mRS) (Farrell et al., 1991) before 
stroke as well as 7 days and 3 months afterwards (note that mRS=6 was added to the 
original mRS, indicating death (Mateen et al., 2009)). As it can be seen, 2 patients died (14 
and 16 days after thrombolysis, respectively), both of cardiac failure (acute pulmonary 
oedema). Neither one had significantly improved after thrombolysis (see above). One more 
patient was left with moderately severe disability (mRS=4) and 3 patients showed very good 
outcome (mRS=0-1).  
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Fig. 2. mRS score before stroke, 7 days and 3 months after it in each patient. One asterisk 
indicates the patient in whom treatment was aborted before of gingival bleeding after 25’, 
when approximately 50% of the full rTPA dose had been received. Two asterisks indicate 
the patient to whom the reduced rTPA dose of 0.67 mg/Kg was administered because she 
had already received 500 mg ASA i.v. 
3. Discussion 
The present report has the obvious limitation of being retrospective, nevertheless we believe 
that it has some interest given the extreme paucity of literature reports on thrombolysis in 90 
y.o. patients or older. To the best of our knowledge, so far only one such report exists in the 
literature (Mateen et al., 2009), while another recently published paper reports a comparison 
between two different databases (Mishra et al., 2010). Our findings are in agreement with 
those report, as far as they confirm that i.v. thrombolysis with r-TPA is reasonably safe in 
these patients. In our patients no treatment-related worsening occurred, and no intracranial 
symptomatic haemorrhage was observed. Retrospectively, abortion of therapy upon 
gingival bleeding may have been excessive (in the other case of minor gingival bleeding the 
full dose was still given with no harm). Death occurred in two of the three unimproved 
cases 14 and 16 days after thrombolysis because of cardiac failure, unrelated to treatment. 
Three out of six patients improved upon thrombolysis. Although this finding is obviously 
encouraging, randomized clinical trials are needed to reach firm conclusions that may be 
applied to the general population of 90 y.o. patients or older. Finally, we note that our 
patients were not handled rapidly by hospital personnel because it was initially believed 
that their old age should have ruled out thrombolysis. This resulted in a significant delay of 
treatment (see above), that has probably reduced the chances of good outcome in our 
patients (Lees et al., 2010). This finding strongly suggests that stroke therapy is a complex 
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issue, one that, whenever possible, should be managed by stroke physicians having specific 
competence and experience. 
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